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Abstract
Dementia occurs with a frequency of 10–12% in the entire geriatric population and 33–50% in people over 90 years of age. The most common cause 
of dementia are: Alzheimer’s disease, rarely vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinson’s disease with 
dementia. There are no medicaments to prevent dementia and effectively treat it. The treatment only slows the progression and improves the qual-
ity of life of the patient and caregiver. Taking care of a patient with dementia burdens the caregiver. As the disease progresses, care time extends 
even to the entire day. Over 90% of caregivers in Poland are family carers. Over 90% of patients stay in their own home until death. The cost of care 
is high and increases with the duration of the disease. In the case of agitated patients, the cost is higher. Institutional care is more expensive than 
home care. In Poland, there are no good system solutions in care for a dementia patient. Caregivers do not receive proper support from the govern-
ment and subordinate units.
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Introduction
Przygotowanie do wydania elektronicznego finansowane w ramach umowy  
637/P-DUN/2019 ze środków Ministerstwa Nauki i Szkolnictwa Wyższego  
przeznaczonych na działalność upowszechniającą naukę.
According to the definition of the World Health Organi-
zation, society is considered to be demographically old 
if the percentage of people aged ≥ 65 years exceeds 7%. 
Poland reached this age threshold in the second half of 
the twentieth century, and the aging of the population 
has now become a very significant and growing prob-
lem. In 1990 the percentage of population aged 65 or 
above in our country was 10.1%, in 2000 it increased 
to 12.3%, in 2010 to 13.4%, in 2016 to 16.1%, and 
in 2017 to 16.7% [1]. The reason for this is not only 
the constant extension of human life, but also the de-
creasing number of births, which in effect means a stead-
ily decreasing percentage of people of pre-working age 
compared to people of retirement age. Already in 1998 
in Poland the number of births was lower than the num-
ber of deaths [1]. As a consequence, the number of 
people meeting the health and care needs of a growing 
group of people potentially requiring care is diminish-
ing. The so-called demographic dependency ratio used 
to assess these needs (the percentage of people aged 
≥ 65 in relation to people aged 15‒64) has been grow-
ing significantly over the last few years. Therefore, ac-
cording to forecasts, the index conventionally adopted 
in Poland would amount to the value of 100 in 2000, 
to 102 in 2010, to about 148 in 2020, 189 in 2030, 2012 
in 2040, and 281 in 2050 [2]. This poses a growing chal-
lenge for the health care system and for the social policy 
of the state to secure the health and care needs increasing 
with age. Ageing is inextricably linked with the grow-
ing problem of multiple morbidities, polypharmacy and 
incapacity.
According to the PolSenior study, representa-
tive of the Polish geriatric population, conducted 
in 2007‒2011, 62% of people aged ≥ 65 years report-
ed multiple morbidities, defined as the existence of at 
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least 2 diseases (mean age of the studied group was 
79.4 years) – of the group, 43% had at least 3 diseases 
and 29% had 4 or more diseases [3]. The most common 
diseases in the study population were of cardiovascu-
lar type: hypertension in 61%, arrhythmia in 36% and 
ischaemic heart disease in 22%. Diabetes was reported 
in 19% of the population, respiratory diseases in 18%, 
osteoporosis in 18%, thyroid diseases in 12%, heart 
failure in 11%. Of the people analyzed in the PolSen-
ior study (taking into account patient history), more 
than 10% reported the occurrence of mental diseases, 
including dementia and depression. However, screen-
ing diagnostics of dementia and depression carried out 
in the cited project showed a much more frequent preva-
lence of these diseases in old age. Cognitive dementia 
was found in 12.1%, mild cognitive disorders, not yet 
fulfilling the criteria of dementia, were found in anoth-
er 36%. Depression of various severity was observed 
in about 30% of the studied population [4].
In addition, the PolSenior study revealed a huge 
prevalence of sensory disabilities: visual disturbances 
were observed in 40% of elderly people, hearing dis-
orders in 32%, balance disorders and falls in 30%. In 
a year, a fall occurred in every 3 persons over 65 years 
of age, in every second person over 80 years of age, with 
such complications as: injuries, fractures, increased risk 
of incapacity and institutionalisation (the consequenc-
es of falls constitute 40% of the causes of admissions 
to nursing homes), loss of independence, reduced quality 
of life, increased prevalence and mortality [5].
With age, there is also a significant deterioration of 
motor and self-service abilities. According to a study by 
PolSenior of people aged 65‒69, about 77% of men and 
88% of women are still independent in everyday life, 
which means that they do not need any help in perform-
ing such activities as: making a phone call, preparing 
a simple meal, doing basic shopping, taking medicines, 
disposing of their own money. However, in advanced old 
age, after the age of 90, only 14% of men and 7% of 
women are independent in these activities. At the thresh-
old of old age, women are fitter and they also live longer 
than men (currently in Poland the average age for women 
is 82 years, for men – 74) [1]. Late old age is less com-
mon for men, but in this period of life they are more able 
than women. The reason for such a clear deterioration of 
functional efficiency with age is primarily the growing 
cognitive disorders, as well as the deterioration of sen-
sory and locomotor organs, and the previously discussed 
multiple morbidities [5].
In the light of the above mentioned coexisting dis-
eases and disabilities, the care of a patient with cogni-
tive dementia is a very difficult and complex issue, es-
pecially in late old age. Dementia, due to the nature of 
the disease, is one of the most important large geriatric 
syndromes, constituting one of the most frequent and 
most difficult health problems in the elderly popula-
tion. It significantly deteriorates the quality of life of pa-
tients, generates immense costs of therapy and care, and 
in the advanced period of disease is the main reason for 
institutionalization.
Diagnosis of dementia
According to the most commonly used WHO definition 
in the world (ICD-10, 1992), dementia is a syndrome 
caused by a brain disease, usually of a chronic or pro-
gressive nature, where higher cortical functions (cogni-
tive functions) are disturbed, such as memory, thinking, 
orientation, understanding, counting, learning ability, 
language and assessment. According to this definition, 
cognitive impairment is usually accompanied, or some-
times preceded, by disturbances in the emotional-moti-
vational sphere and decrease in control over behavior. 
They are often a bigger problem in therapy and care than 
the axial symptoms of dementia, which are cognitive 
disorders [6].
Dementia is most often caused by neurodegen-
erative changes, including Alzheimer’s dissease (AD), 
which accounts for 35‒70% of all dementia cases [7, 8]. 
The slightly rarer neurodegenerative disorders include 
dementia with Lewy bodies (DLB, 20‒25%), frontotem-
poral dementia (FTD, 10‒15%) and Parkinson’s disease 
with dementia (PDD, approx. 5%).
Vascular dementia (VaD) is a less common cause of 
dementia than neurodegenerative diseases. The Vascular 
Dementia (VaD) disorders account for 30% of all cases 
of this syndrome. However, pure vascular dementia is 
rare (about 5% of all dementias) and most often coexists 
with AD. 
Occasionally dementia may be caused by other 
diseases, including: progressive supranuclear palsy, 
corticobasal degeneration, Creutzfeldt-Jakob disease, 
Hakim-Adams syndrome, Huntington’s disease, heredi-
tary congophilic angiopathy, dementia in the course of 
Down’s syndrome [6]. 
Cognitive dysfunctions in geriatric patients may 
also be caused by factors causing the so-called pseudo-
dementia, also referred to as potentially reversible de-
mentia. The group of such causes includes: diseases of 
the central nervous system (both primary and metastatic 
brain tumors, chronic subdural hematoma and other con-
sequences of craniocerebral injuries, neuroinfections), 
deficiency syndromes (mainly vitamin B12 deficiency), 
somatic diseases (hypothyroidism, poorly controlled 
diabetes, especially with chronic hypoglycaemia, organ 
failure, especially of the heart, respiratory system, liver 
or kidneys, water-electrolyte metabolism disorders, es-
pecially hyponatremia and hypernatraemia, inflammato-
ry and neoplastic diseases). Cognitive dysfunctions may 
also be caused by abnormalities in the pharmacotherapy 
of elderly people (they may occur especially when using 
neuroleptics, sedatives and sleeping pills, as well as an-
algesics). The diagnosis of cognitive disorders in some 
cases should also take into account the alcoholic back-
ground and its occurrence in mental diseases (especially 
in depression and schizophrenia) [6].
Prevalence of dementia
The prevalence of dementia in the entire geriatric popu-
lation is, according to various studies, about 10‒12%, 
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with a marked increase in the prevalence of this dis-
ease in subsequent age groups. At the threshold of old 
age, dementia is observed in just a few percent of peo-
ple, but after 80 years of age – in about 20%, and ≥ 90 
years of age – in as many as 33‒50% of people [9]. 
In the PolSenior study, dementia-related cognitive dys-
function increased from 9.5% in the 65‒69 age group, 
to 10.1% in the 70‒74 age group, 14.5% in the 75‒79 
age group, 15.6% in the 80‒84 age group, and 20.9% 
in the 85‒89 age group. In the oldest group (aged 90 
and above) cognitive dementia-indicating disorders 
were found in 34.4% of respondents [10].
The enormous prevalence of dementia in the elderly 
population is a very important problem from the point of 
view of geriatric care in the broad sense of the term. This 
also results in enormous costs associated with the pro-
vision of appropriate care both in the patient’s place of 
residence and in the form of institutional care.
Pathogenesis of dementia
The main pathogenetic factor in Alzheimer’s disease 
is the presence of pathological proteins, among them 
β-amyloid (Aβ) and hyperphosphorylated tau pro-
tein, which lead to neuronal loss, deterioration of their 
function and damage to synaptic connections, mainly 
in the hippocampal area. β-amyloid is characterized by 
aggregation and extracellular deposition between neu-
rons in the form of amyloid plaques. On the other hand, 
tau protein accumulates inside neuronal cells, causing 
neurofibrillary degeneration. Both pathological proteins 
lead to damage and death of neurons, which results 
in a decrease in the production of brain messengers, 
mainly acetylcholine. The level of other neurotransmit-
ters such as noradrenaline, serotonin and dopamine is 
also reduced in this type of dementia.
Except for sporadic cases of familial forms of AD, 
the current state of knowledge finds no genetic back-
ground for these disorders. More than 95% of cases of 
dementia in the course of Alzheimer’s disease have no 
hereditary etiology. In view of the above, genetic testing 
is not currently recognized as a useful and recommended 
tool in routine diagnosis of the disease. Age is the only 
indisputable risk factor for Alzheimer’s disease. Other 
discussed predisposing factors for AD include: lack of 
education, low physical activity, poor family and social 
contacts. In recent years, the significant role of vascular 
factors in the risk of developing AD has also been in-
creasingly emphasized.
Dementia with Lewy bodies is caused by the pres-
ence of Lewy bodies in the neo-cortex and limbic cor-
tex bodies containing deposits of α-synuclein protein. 
The cause of these changes is unknown, and the genetic 
background of the disease has not been proven.
In frontotemporal dementia, deposition occurs 
in the area of the frontal and/or temporal lobes in neu-
rons or glial cells of inclusion bodies consisting of hy-
perphosphorylated tau protein or ubiquitin. Approxi-
mately 30‒50% of FTD cases have a family history of 
the condition.
Vascular dementia has a multifactorial, complex is-
chemic or hemorrhagic etiology. It occurs in the course 
of various cerebral vascular diseases (massive and minor 
strokes as a complication of large vessel disease, com-
plications of small vessel disease, intracerebral hemor-
rhage, vasculitis, angiopathy) [6, 8, 9].
Diagnosis and recognition
According to current knowledge, a 100% pre-mortem 
diagnosis of dementia in the course of Alzheimer’s dis-
ease is not possible; this diagnosis is only likely. Unam-
biguous confirmation of the diagnosis is possible only 
after histopathological examination of the brain tissue. 
In the screening diagnosis of cognitive impairment, 
the Mini Mental Test Examination (MMSE), Clock 
Drawing Test (CDT) and the Montreal Cognitive As-
sessment (MoCA) are most commonly used. The MoCA 
test is especially recommended for the diagnosis of early 
stage dementia and mild cognitive impairment (MCI) 
usually preceding the clinical stage of Alzheimer’s dis-
ease or other types of dementia. In psychological diag-
nostics of cognitive disorders, the following are most of-
ten recommended: Trail Making Test, California Verbal 
Learning Test, Verbal Fluency Test, Rey Complex Figure 
Test, and ADAS-Cog (Alzheimer’s Disease Assesment 
Scale – Cognitive Subscale). According to current cri-
teria, in the diagnosis of dementia there is also a need 
to conduct a neuroimaging examination, primarily to ex-
clude other causes of cognitive impairment. The Polish 
Alzheimer’s Society (Pol. PTA) recommends nuclear 
magnetic resonance imaging (MRI) as the main diag-
nostic tool in clinical practice. PET and SPECT tests are 
only recommended for differential diagnosis in doubtful 
cases. In situations where it is not possible to perform an 
MRI examination, computed tomography is used.
Determination of biomarkers in the cerebrospinal 
fluid (in which there is a decrease in the level of Aβ42 
peptide, an increase in hyperphosphorylated tau pro-
tein) also plays a supporting role in the diagnosis of de-
mentia. However, the use of biomarker tests for routine 
clinical practice is not recommended, and a diagnosis of 
dementia in AD cannot be made solely based on the re-
sults of biomarker tests in cerebrospinal fluid or neuro-
imaging [6].
Currently, in the diagnosis of dementia in AD most 
commonly used are the criteria based on 1994 DSM-IV, 
1992 ICD-10 (WHO) and 2011 NIA/AA (National In-
stitute on Aging/Alzheimer’s Disease Association) [6]. 
According to the NIA/AA criteria, three stages of Alz-
heimer’s disease are distinguished. The first two of them 
(asymptomatic – preclinical and mild cognitive impair-
ment) precede the onset of clinical symptoms of demen-
tia for many years. According to these clinical criteria, 
the basis for the diagnosis of mild cognitive impairment 
are the following symptoms: concern related to a change 
in cognitive performance reported by the patient, in-
formant or clinician, objective evidence of deteriora-
tion in one or more cognitive areas, but the independent 
ability to function daily is maintained and there are no 
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symptoms of dementia. According to the current state 
of knowledge, MCI is not an indication for the inclu-
sion of pharmacotherapy, although in the vast majority 
of cases the conversion of MCI to dementia occurs over 
time. Studies have shown that in people ≥ 65 years of 
age, about 15% of mild cognitive impairment develop 
into dementia in 2 years, and in 10 years of observa-
tion – over 90% [11, 12]. However, the results of previ-
ous studies have not proven the long-term effectiveness 
of any pharmacotherapy in the prevention of dementia, 
and the risk of side effects and the cost of therapy far 
outweigh the possible benefits [11, 12].
In the diagnosis of dementia with Lewy bodies, 
the 2005 criteria according to McKeith et al. are most 
often used, among which the most important are: fluc-
tuation of disorders, systematic visual hallucinations, 
attention deficit disorder and Parkinson’s symptoms [6].
Frontotemporal dementia occurs in three basic types: 
the frontal variant, semantic dementia and progressive 
aphasia without speech fluency. The diagnosis of this 
type of dementia is based on several different criteria 
that enable the diagnosis of particular types of patholo-
gies belonging to this group of disorders (1994 criteria 
according to Lund and Manchester Group, 1998 criteria 
according to Neary et al., and 2001 criteria according 
to McKhanna et al.) [6].
Vascular dementia is a complex, multifactorial eti-
ology, which in consequence determines a very diverse 
clinical picture, depending on the size, number and lo-
cation of lesions. There are also many different divi-
sions and diagnostic criteria for this type of dementia. 
According to PTA, the most commonly used criteria 
are NINDS-AIREN (National Institute for Neurologi-
cal Disorders and Stroke with the Association Interna-
tionale pour la Recherche et l’Enseignement en Neuro-
sciences, 1993) [6]. 
In the diagnosis of dementia in Parkinson’s disease 
the 2007 criteria according to Emre et al. are currently 
in force [6]. The diagnosis of this type of dementia must 
also meet the so-called one-year condition, which means 
that clinical symptoms of cognitive disorders occur at 
least one year after the onset of motor disorders. If these 
symptoms occur earlier, then LBD should be suspected.
Symptoms of dementia
The course of dementia in Alzheimer’s disease is most 
often divided into three stages: light (mild), medium 
(moderate) and significant (deep). In the first stage of 
the disease, the patient is still relatively independent 
in self-service, although there may already be slight 
difficulties in the disposal of money, shopping, using 
credit cards and performing other more complex activi-
ties related to everyday functioning. During this period 
of illness, it is typical to forget about recent events, dif-
ficulties in finding words, descriptive names of objects, 
frequent repetition of the same questions, partial disor-
der in time and space orientation. There are no clear dif-
ficulties in understanding speech, personality changes or 
movement disorders.
The second stage of dementia in the course of Alz-
heimer’s disease is characterized by more severe distur-
bances of fresh and distant memory, and greater difficul-
ty in finding words. There are already initial difficulties 
in understanding speech, dressing up and maintaining 
personal hygiene. Difficulties in managing money are 
more severe than in the first period of illness, and there 
is also an inability to make complex decisions. The first 
Parkinson movement symptoms may also appear. Dur-
ing this period of dementia, behavioral disorders are most 
often accompanied by these symptoms. These symptoms 
can sometimes appear in the first period of the disease, or 
occur only in the third stage of dementia. They are recog-
nized by the International Psychogeriatric Association as 
an integral part of dementia and referred to as behavioral 
and psychological symtomps of dementia (BPSD).
According to the new nomenclature and new guide-
lines updated in 2018 for the management of behavioral 
disorders in dementia, these changes are now also re-
ferred to as neuropsychiatric symptoms (NPS) [13].
The authors of these guidelines divided NPS into 
three groups: behavioral, affective and psychotic dis-
orders. The most common behavioral disorders in de-
mentia include: agitation, anxiety, purposeless walking, 
verbal and/or physical aggression, shouting, swearing, 
hostility, constantly asking the same questions, stub-
bornness, negativity, defiance, apathy, passivity, social 
withdrawal, clingy attitude towards the caregiver, dis-
inhibition, including sexual disinhibition, shortening 
the distance in interpersonal relationships leading to in-
appropriate social behavior. Of affective disorders most 
common in dementia are emotional lability, depression, 
anxiety, worrying, phobias, sleep-wake disturbances, 
sometimes cheerfulness or euphoria, dysphoric reactions 
and sometimes catastrophic reactions. Among the vari-
ous psychotic symptoms in dementia, delusions (which 
may often be paranoid as a result of cognitive disorders, 
e.g. robbery delusions), hallucinations, as well as misi-
dentification syndromes are most commonly observed.
Of all the listed behavioral disorders in the moderate 
period of dementia in Alzheimer’s disease, apathy, anxi-
ety, irritability, and depression are the most common. 
In the severe form of dementia observed are the grow-
ing scarcity of vocabulary, uttering simple, often illogi-
cal sentences, then only single words, often distorted, 
or newly formed, then single syllables, and ultimately 
aphonia. There is a lack of speech understanding, no per-
sonal hygiene, and loss of sphincter control. As the dis-
ease progresses, BPSD symptoms usually increase, es-
pecially agitation, anxiety, aggression, and psychotic 
symptoms. The advanced period of Alzheimer’s disease 
may be associated with Parkinsonian movement disor-
ders, gait and balance disorders, seizures and involun-
tary movements.
In dementia with Lewy bodies, memory disturbances 
may not appear in the early stages of the disease, but 
from the beginning psychotic symptoms, apathy, irrita-
bility, repeated, systematized and long-lasting visual hal-
lucinations are present. A characteristic of this type of 
dementia is the fluctuation of symptoms, imbalance with 
Zeszyty Naukowe Ochrony Zdrowia20
wyzwania dla opieki zdrowotnej
recurrent falls, extrapyramidal symptoms (occurring 
in approximately 70% of patients) and a high sensitivity 
to neuroleptics. 
FTD in the frontal form begins with a progressive 
personality change, behavioral disorder, lack of empa-
thy, criticism and inhibition (including sexual), more 
severe than in other types of dementia. In the temporal 
variant (also referred to as semantic dementia) from 
the beginning of the disease there are deep acquired (se-
mantic) memory disorders with a clear loss of verbal 
memory, speech is fluent, but loquacious (with the so-
called empty speech). In the third variety of the disease 
(progressive aphasia without fluency of speech), patients 
have difficulty building sentences, writing and reading 
from the beginning, while their understanding of speech 
is relatively good.
Amongst the various forms of vascular dementia, 
most commonly distinguished are the subcortical de-
mentia, which is caused by multiple lacunar infarcts 
and white matter damage, and multi-infarct dementia 
caused by multiple cerebral infarctions, mainly located 
in the cerebral cortex. Subcortical dementia is charac-
terized by a loss of planning ability, visual-spatial ori-
entation, and executive functions. Memory disorders 
are less severe, among the symptoms of NPS are mainly 
depression, emotional lability and personality disorders. 
These symptoms are accompanied by features of pyram-
idal and extrapyramidal syndromes, pseudobulbar palsy 
and sphincter incontinence (in VaD, the lack of sphinc-
ter control may occur earlier than in other types of de-
mentia). Focal neurological symptoms coexist in multi-
infarct dementia with cognitive impairment. In VaD, 
the symptoms are quite diverse depending on the location 
of the lesions. In the presence of changes in the frontal 
and/or temporal lobes, the symptoms of the disease are 
similar to the FTD picture. In turn, aphasia, agnosia and 
apraxia often occur with damage to the parietal lobes, 
which may resemble the picture of Alzheimer’s disease. 
However, in contrast to AD, vascular dementia is most 
often characterized by an abrupt course (AD is gradual), 
with a significantly worse prognosis. Observations of pa-
tients show about twice as short survival time of patients 
with VaD as compared to patients with AD, and their in-
stitutionalization is twice as frequent.
In the course of Parkinson’s disease, dementia is ob-
served in about 20‒40% of people diagnosed with this 
disease. Conducive to the development of this type of 
dementia are: older age of the patient, longer duration 
of the disease, course of the disease with greater stiff-
ness and severe motor disorders. In the clinical picture of 
PDD prevail the features of subcortical dementia, with 
attention deficit disorder, impaired executive, visual-spa-
tial functions, slowing of thought processes (bradyphre-
nia), verbal fluency disorder, and lack of initiative. These 
symptoms are often accompanied by depression, sleep 
disturbances, apathy, agitation with aggression, anxiety 
and hallucinations, and delusions. Symptoms of this type 
of dementia may resemble dementia with Lewy bodies, 
but movement disorders occur earlier here and precede 
the features of dementia by at least a year, while in LBD 
the symptoms of dementia and hallucinations appear 
in parallel with movement disorders.
Regardless of the etiology, every case of dementia al-
ways has an unfavorable prognosis and a similar clinical 
picture is observed in all types of dementia. In the termi-
nal period of the disease, which determines the final part 
of major dementia, the patient already becomes com-
pletely dependent on the care of other people, does not 
signal any of his physiological needs. As a result, pro-
gressive weakness and disability lead to being bedridden 
and related medical problems, including thromboembol-
ic complications, pressure sores, muscular atrophy, con-
tractures, malnutrition, infections, especially pneumonia 
and urinary tract infections. These complications are usu-
ally the direct cause of the patient’s death. Deterioration 
of mobility and functional dementia can occur gradually 
or rapidly, most often after falls, especially when there is 
a complication in the form of fracture of the proximal fe-
mur. The treatment of choice should then be surgery, but 
due to many contraindications, especially in the presence 
of other somatic diseases, the procedure is often aban-
doned, which in the case of geriatric patients, in practice 
means almost 100% mortality within a year. 
Dementia prevention
The risk of developing dementia is primarily influenced 
by non-modifiable factors (mainly age, to a lesser ex-
tent, genetic conditions), but also by modifiable factors, 
and preventive measures are currently focused on them. 
Based on the results of available research, recommenda-
tions on diet and lifestyle in the prevention of dementia 
have been developed by experts. The most important of 
these recommendations include: reducing the consump-
tion of animal fats, increasing the consumption of veg-
etables, fruits, whole grains, fish containing polyunsatu-
rated fatty acids, as well as avoiding vitamin preparations 
containing iron and copper. Regular physical activity and 
reduction of cardiovascular risk factors, which increase 
not only the risk of vascular dementia but also Alzhei-
mer’s disease, is also recommended for prophylaxis. It 
is also recommended to intensify mental activity, which 
increases cognitive reserve. According to recent studies, 
the inclusion of these non-pharmacological prophylactic 
methods, mainly by reducing the most important seven 
modifiable risk factors for Alzheimer’s disease (physical 
inactivity, hypertension, depression, nicotinism, obesity, 
diabetes, low education) has reduced the trend to in-
crease the incidence of cognitive impairment with aging 
population and can potentially reduce the number of AD 
patients by up to 28.3% [14].
Non-pharmacological treatment in dementia
In the treatment of dementia also non-pharmacological 
methods and pharmacotherapy are used. Non-pharma-
cological methods include: validation (stimulation of 
correct social behavior, reduction of anxiety), cogni-
tive therapy (training of memory, orientation in time 
and space), reminiscing, occupational, environmental 
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and music therapies. These methods alleviate mainly 
behavioral disorders in dementia, improve the qual-
ity of life of patients, facilitate falling asleep, and re-
duce the need for neuroleptics, but have less impact 
on the intensity of cognitive disorders. In diagnosed 
dementia, the importance of lifestyle modification and 
diet recommended to prevent dementia has not been 
proven to prevent disease progression. The detection 
and treatment of malnutrition, which is an independent 
risk factor for death in dementia patients, is of great im-
portance. According to the recommendations of the Eu-
ropean Society for Clinical Nutrition and Metabolism 
(ESPEN), treatment of malnutrition must be an inte-
gral part of dementia therapy, which does not inhibit 
the progression of cognitive disorders, but improves 
prognosis and quality of life of patients. In the case of 
eating disorders in patients with mild to moderate de-
mentia, at the time of acute disease increasing protein 
and energy demand (e.g. infections, perioperative pe-
riod) it is possible to temporarily apply feeding through 
a probe or percutaneous endoscopic gastrostomy. In 
the advanced stage of dementia, especially in its ter-
minal phase, despite the presence of nutritional traits, 
the difficulties in swallowing, parenteral nutrition, in-
tragastric or percutaneous endoscopic gastrostomy 
does not improve prognosis, and the use of these in-
vasive methods increases patients’ anxiety and dete-
riorates their quality of life, and according to ESPEN 
guidelines, the above mentioned methods of therapy 
are no longer recommended. However, these guidelines 
recommend hyadration of patients in the terminal de-
mentia period, oral feeding with the use of all possible 
methods supplementing the food supply (use of oral 
rich protein and vitamin preparations, liquid thickeners, 
especially at the risk of choking) [15]. 
Pharmacotherapy in dementia
So far, no drugs have been invented that can effectively 
treat any type of dementia. The recommended pro-cogni-
tive drugs only slow down the progression of the disease 
and, what is important, improve both the quality of life 
of patients and their caregivers. Currently, only 3 drugs 
are registered in Poland to treat dementia. Two of them 
(donepezil and rivastigmine) belong to the group of ace-
tylcholinesterase inhibitors (AChEI), inhibiting the en-
zyme that is responsible for excessive degradation of 
acetylcholine in the brain. The third drug, memantine, 
is an NMDA receptor antagonist (N-methyl-D-aspartic 
acid). It has a neuroprotective effect against the toxic ef-
fects of glutamic acid and against the accumulation of 
β-amyloid deposits and the formation of tau protein. 
Donepezil and rivastigmine are recommended for 
mild to moderate dementia, while memantine is recom-
mended for moderate to severe dementia. According 
to the guidelines of the Polish Alheimer’s Society and 
other scientific societies dealing with dementia, the use 
of any other drugs is not recommended. 
AChEI drugs are recommended as the main drugs, 
whereas monotherapy with memantine is recommended 
especially for contraindications to inhibitors, lack of their 
effectiveness or poor tolerance. The use of combined 
therapy with memantine is recommended in the absence 
of any significant improvement after AChEI. 
Before the use of AChEI drugs, especially in older 
patients with concomitant multiple diseases, the presence 
of possible contraindications to their use and the risk of 
side effects versus the benefits of therapy should be care-
fully considered. The main contraindications for the use 
of AChEI drugs are: arrhythmias with bradycardia, sinus 
node disease, active peptic ulcer disease and bronchial 
asthma. AChEI, through its cholinomimetic effect, may 
be burdened with a significant risk of bradycardia and 
life-threatening arrhythmias. The results of many stud-
ies indicate a significant increased risk of fainting, falls 
and doubling the risk of hospitalization in patients re-
ceiving donepezil or rivastigmine [16]. The administra-
tion of these drugs should be started very carefully and 
in initial low doses to maximally reduce the risk of ad-
verse effects (bradycardia, nausea, diarrhoea, constipa-
tion, vomiting, anxiety, difficulty in urination, fluctua-
tions in blood pressure). The results obtained in recent 
years also draw attention to the fact that AChEI therapy 
increases the risk of malnutrition in old age, especially 
in more advanced stages of the disease. This is anoth-
er important indication to consider the advisability of 
therapy in older patients, often malnourished, in whom 
the risk of side effects from the gastrointestinal tract may 
reach up to several percent [17, 18]. Currently, stud-
ies are being conducted on the benefits of discontinua-
tion versus continuation of the therapy with these drugs 
in advanced dementia [19].
If the decision is made to treat dementia with meman-
tine in older patients, the renal function during the thera-
py should be monitored due to the excretion of the drug 
in urine in a non-metabolized form. At 40‒60 ml/min 
GFR, the dose should be reduced to half of its original 
value, and in the case of more advanced renal failure, 
the dose should be discontinued. It should be remem-
bered that in older patients, the glomerular filtration ca-
pacity decreases physiologically, which at the very start 
of therapy may be an indication for drug dose reduction.
Studies on new forms of dementia pharmacother-
apy (mainly monoclonal antibodies, which preferen-
tially show the ability to bind to β-amyloid and as a re-
sult of dissolution of β-amyloid deposits and inhibitors 
of γ-secretase, which participates in the pathway of 
β-amyloid formation from protein precursor) have so 
far not demonstrated the efficacy of these drugs, which 
would exceed the risk of their adverse effects. Also cer-
ebrolysin, which is a mixture of peptides, recommended 
as a potential neurotrophic factor stimulator for several 
years, has not yet been explicitly registered in the treat-
ment of dementia, despite the fact that there are increas-
ing scientific reports on its effectiveness and safety [20].
Treatment of behavioral disorders in dementia
Another difficult problem is the treatment of behavio-
ral disorders and psychotic symptoms in dementia. As 
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the results of most studies show, these disorders occur 
in 80‒100% of patients. The recommended form of NPS 
therapy, apart from elimination of possible factors stimu-
lating their occurrence (pain, dyspnea, environmental, 
social and psychological factors), is early inclusion of 
AChEI and/or memantine into treatment. The recommen-
dations clearly emphasize that classical antipsychotics 
(including haloperidol and pernazine) cannot be an alter-
native to second-generation neuroleptics, due to a much 
higher risk of side effects and even deaths. The results 
of many meta-analyses show that even new neuroleptics 
are not devoid of the risk of cardiac arrhythmias, falls, 
weakness, drowsiness, orthostatic hypotension, metabol-
ic disorders, strokes and increased risk of mortality. For 
these reasons, it is recommended to use only small atypi-
cal neuroleptic doses (quetiapine, tiapridal, olanzapine, 
risperidone) administered for the shortest possible period 
of time, if necessary. According to the latest Polish rec-
ommendations included in the updated rules of therapy 
in neuropsychiatric disorders in dementia, the best safety 
profile among antipsychotics is quetiapine and tiapridal. 
If new neuroleptics prove ineffective, low doses of car-
bamazepine or valproate derivatives may be considered 
in agitation. In sleep disorders in dementia, the so-called 
sundown syndrome, and in moderate anger and aggres-
sion, trazodone is recommended as the first-line drug. 
However, benzodiazepine drugs should be avoided 
in older patients because of the high risk of side effects 
(excessive sedation, walk and balance disturbances, 
falls, addiction and even increased risk of mortality). In 
older patients, due to poorer metabolism and elimination 
of these drugs from the system, the risk of interaction 
and side effects of benzodiazepine are much higher than 
in younger patients [13]. 
Dementia patient care
As the disease progresses, the patient with dementia be-
comes increasingly dependent as far as self-service is 
concerned and increasingly reliant on the caregiver, ini-
tially mainly for complex everyday activities, then also 
for the satisfaction of basic life needs. Initially, the pa-
tient requires only periodic control, supervision, support 
and assistance in the implementation of more complex 
measures concerning his or her everyday life. There-
fore, it can be only occasional help, often several times 
a week. However, studies from recent years have shown 
that even in this early stage of the disease, the quality of 
care for demented patients may not be sufficient. Often, 
the caregiver does not notice growing cognitive disor-
ders, and the patients themselves, due to better distant 
memory, appear to have less severe disorders. In a study 
including a 7-thousand Baltimore geriatric popula-
tion in its own environment, it was shown that among 
people with probable dementia, but not yet diagnosed, 
compared to people who have already been diagnosed 
with the disease, the greatest problem is that of self-
negligence – the engaging of a patient with cognitive 
disorders in potentially dangerous actions, if they were 
inappropriately implemented. These activities included 
financial management, driving vehicles, preparing hot 
meals, proper use of medicines, control visits at the clin-
ic [21]. The fact of how often this problem remains un-
noticed and the symptoms of dementia are mistakenly 
attributed to the aging process itself and considered to be 
a kind of age norm, is confirmed by the fact that despite 
the improvement in the diagnosis and treatment of de-
mentia, only about 15‒20% of these patients have their 
problem properly diagnosed and undergo appropriate 
therapy [22].
As dementia progresses, patient care takes more 
and more time and changes from helping with everyday 
activities at the beginning of the disease, to permanent 
care and nursing activities at a later stage of the disease. 
According to PTA data, the duration of care increases 
from about 2.4 hours in the first year of disease dura-
tion, to 9 hours in the 5th year of disease, to the entire 
day after 10 years of dementia. According to the data 
of the National Agreement of Alzheimer’s Organisa-
tions published in 2015, about 90% of caregivers are 
family caregivers (including adult children – 62% and 
spouses – 32%). In 70% of cases, the carer of the de-
mented patient is a woman. A significant proportion of 
caregivers are over 70 years of age and face their own 
medical and functional problems at the same time [22]. 
Younger caregivers, on the other hand, are often forced 
to resign from their professional work in order to care 
for demented patients. Studies of the Polish population 
show that the family is still the ‘main care institution’ 
for dementia patients [23]. However, this care is ex-
tremely burdensome and exhausting for the caregiver, 
and the burden is even greater than for caregivers deal-
ing with cancer patients. Caregivers significantly more 
often suffer from cardiovascular diseases, depression, 
degenerative spine, or insomnia [24]. At the same 
time, this burdening care creates a risk of errors and 
negligence in the care of demented patients, which, ac-
cording to recent studies, can be observed even in one 
in five patients [25].
The burden on the informal carer depends not 
only on the severity of the disease and symptoms, but 
also on the support provided by different systemic so-
lutions in a given country. A comparative analysis of 
this problem conducted in 8 European countries (Esto-
nia, Finland, France, Germany, the Netherlands, Spain, 
Sweden, the United Kingdom) showed that the bur-
den on caregivers was highest in Estonia and lowest 
in the Netherlands [26].
Costs of care in dementia 
Dementia is a huge economic burden and the cost of care 
increases with the severity of the disease. An analysis of 
these costs in developed countries shows that the costs 
of care and treatment of dementia are among the highest 
in the world, after cancer, cardiovascular diseases and 
stroke [27]. There are no data on the cost of care for de-
mentia patients in Poland. 
According to the latest research meta-analyses, the av-
erage total annual cost of dementia care in Europe amounts 
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to 32,506.73 €, compared to 42,898.65 € in the United 
States [28]. As the population ages and the risk of demen-
tia increases, these costs are expected to be increasingly 
borne by society. These figures do not include informal 
care and other indirect costs, including gratuitous care 
provided by family carers [29]. The GERAS study com-
paring expenditure on dementia care conducted in three 
countries with similar economic status (UK, Germany 
and France) showed that it differed significantly from one 
country to another and grew significantly in the subse-
quent three stages of dementia. Total monthly care costs of 
mild dementia in France were 1,418, in moderate demen-
tia – 1,737 € and 2,453 € in significant dementia. In Ger-
many, this expenditure was respectively 1,312 €, 2,412 € 
and 3,722 €, while in the UK it was 1,621 €, 1,836 € and 
2,784 €. [30, 31]. In Spain, the GERAS II study showed 
that care for patients with mild dementia is 1,514 € per 
month, for patients with moderate dementia 2,082 € 
per month, and increases to 2,818 € in the third stage of 
the disease. In the same project, in the Italian population, 
monthly costs in the first stage of the disease were esti-
mated at 1,850 €, in the second stage, which was interest-
ingly reduced to 1,552 €, and in the third stage increased 
again to 2,728 €. This surprising reduction in the cost of 
care in the moderate stage of the disease is explained by 
the effectiveness of the memantine included in the treat-
ment at this stage of the disease [33]. 
The research also clearly emphasizes that institu-
tional care for dementia patients is much more expen-
sive than home care [34, 35]. Therefore, in order to delay 
institutional care, many countries support family car-
ers and invest in community care services [36, 37]. It 
has also been shown that not only does the duration of 
the disease generate higher care costs, but also behavio-
ral disorders in dementia, especially agitation. In the case 
of the predominant symptom, the cost of care may even 
double [38‒40]. 
Dementia patient care in Poland 
According to estimates from the PolSenior study and 
the report of the Polish Alheimer’s Society, there are 
about 500‒600 thousand people with dementia in Po-
land, including about 300 thousand with Alzheimer’s dis-
ease [4, 22]. However, there is no complete register of 
dementia patients in our country, which exists in other 
EU countries, such as the Swedish computer registration 
system SveDem or the ReDeGi register kept in part of 
Spain [7]. There are also no data on the cost of care for 
dementia patients in our country. 
In Poland, dementia care is provided by two separate 
structures under the Ministry of Health and the Minis-
try of Family, Labour and Social Policy (Pol. MRPiPS). 
The MRPiPS has a Senior Policy Department whose task 
is, among others, to provide non-medical, multidirec-
tional care for patients with dementia. 
There are no services available in our country that are 
specific to people with dementia on a wider scale. Care 
for patients with dementia is provided mainly at home, 
rarely with institutional support in the patient’s place 
of residence or in day-care centers. A small percent-
age of patients remain in 24-hour institutional care. 
There are also Alzheimer’s associations and support 
groups (usually at specialist counselling centers).
Despite the enormous burden of care, much greater 
than in other chronic diseases, in our country, less fre-
quently than in other developed countries, the family 
decide on institutional care. In Poland, 92% of demen-
tia patients stay at home from the onset of the disease 
until death [41]. According to the results of research 
conducted by Karczewska et al., over 75% of caregivers 
declare that they would not decide on institutional care 
of their patients under any circumstances [23]. Family 
carers rarely receive adequate support from the health 
care system, and are usually left to their own devices. 
There is also no legal status of a carer of a person suf-
fering from dementia in our country, and there is no for-
mal support system for family carers. There are also no 
legal solutions that would enable the carer to reconcile 
care with work. The carer of a disabled person may be 
granted a maximum of 14 days’ leave per year to provide 
care for family members, which is definitely insufficient 
in the case of caring for a person with dementia. 
In Poland, dementia is diagnosed by geriatrists, 
neurologists or psychiatrists, and continuation of ther-
apy is carried out by primary care physicians with pe-
riodic specialist check-ups. However, the network of 
diagnostic institutions is definitely insufficient and 
the waiting time for medical consultation and diagnos-
tic tests is very long. There is also insufficient assis-
tance for patients in the form of daily care centers, sup-
port for family carers in the patient’s place of residence 
and the number of inpatient facilities providing 24-hour 
care for patients. In practice, this means that the system 
of commercial services is increasingly developing, both 
in the form of home care and 24-hour care. However, 
it is a form of service available to a small group of pa-
tients and their carers. 
In Poland, there is no integration of health services 
with social welfare and no specific systemic solutions 
for the care of demented patients. Activities under-
taken at the ministerial level (project of the National 
Alzheimer’s Plan, Resolution No. 238 of the Council 
of Ministers of 24 December 2013 covering the as-
sumptions of the Long-term Senior Policy in Poland 
for 2014‒2020) [22] in practice do not translate into 
the quality of care for the demented patient, which is 
still very poor. Compared to other EU countries, Po-
land is still not prepared to face and resolve the chal-
lenge of dementia and create a country that would be 
friendly to people with cognitive disorders – where 
there would be easy access to diagnosis, treatment and 
various forms of institutional care, support for the fam-
ily carer, the possibility of participation of patients 
in daily activities accessible to all without exception, 
without exclusion, social isolation and marginalization. 
Such solutions have already been adopted in many EU 
countries, and in other countries plans and strategies 
for the care of dementia patients are in the process of 
public consultation [42].
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Summary
Dementia is a very important and widespread medi-
cal and care problem in ageing societies. In the light of 
the problems discussed and the results of the many stud-
ies presented, which point out that dementia patient care 
is an immense burden in terms of the time invested and 
the economic and psychological challenges, this problem 
must become an important issue for the currently oper-
ating care system and for the future planning of health 
policy in our country.
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